Farletuzumab

Farletuzumab (MORAb-003) is a monoclonal antibody[1] which is being investigated for the treatment of ovarian cancer.[2][3]

Farletuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetFR-alpha
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6466H9928N1716O2020S42
Molar mass145371.06 g·mol−1
 NY (what is this?)  (verify)

This drug was developed by Morphotek, Inc.

It is targeted at FR-alpha which is overexpressed in some cancers such as ovarian cancer.

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.